GSK's consumer health spinout Haleon started ... a decade – has annual sales of around £10 billion from brands like Sensodyne toothpaste, Voltaren and Panadol painkillers, and Centrum ...

Pfizer has officially kissed goodbye to its consumer health venture by selling its final 7.3% stake in Haleon for a tidy $3.3 ...

GSK said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its ...

The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...

Blujepa, which treats UTIs in female patients aged 12 and up with common and uncomplicated infections, will hit the market in ...

GSK received approval from the Food and Drug Administration for Blujepa to be used as a treatment for some urinary tract infections. Blujepa, or gepotidacin, was approved to treat uncomplicated ...

GSK plc GSK announced that the FDA has approved its oral antibiotic gepotidacin for treating uncomplicated urinary tract ...

Learn More. Just over a year ago, I ran the rule over GSK (LSE: GSK) shares. They looked very cheap and were offering a growing dividend. However, I chose instead to invest in FTSE 100 ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...